RECURSION PHARMACEUTICALS, INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
RECURSION PHARMACEUTICALS, INC. (RXRX) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $31.80 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-02-25
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $31.80M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $36.70M.
- 2025-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $46.40M.
- 2025-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $52.00M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2025-12-31 | $31.80M 10-K · filed 2026-02-25 |
| 2025-09-30 | $36.70M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $46.40M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $52.00M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $59.20M 10-K · filed 2025-02-28 |
| 2024-09-30 | $38.20M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $38.80M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $43.90M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $32.60M 10-K · filed 2024-02-29 |
| 2023-09-30 | $39.60M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $37.60M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $37.10M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $29.10M 10-K · filed 2023-02-27 |
| 2022-09-30 | $32.80M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $37.80M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $40.90M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $31.70M 10-K · filed 2022-03-23 |
| 2021-09-30 | $27.90M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $28.60M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $22.00M 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |